Search for content, post, videos
Advertisement

TikoMed appoints leading ALS expert to its SAB

The company has announced the appointment of Professor Jeremy Shefner, MD, PhD at the Gregory W. Fulton ALS & Neuromuscular Disease Center, the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA as the third member of its newly-formed Scientific Advisory Board (SAB).

“We are thrilled to welcome Dr. Shefner to join our SAB,” says Adam Bruce, Founder, Chairman of the Board and CEO, of TikoMed. “We are confident that his expertise within biomarker development for ALS diagnosis and experience from the NEALS consortium will be of great value for progressing our drug candidate ILB for treatment of ALS through the clinical program.”

Jeremy Shefner

Professor Shefner is a neurologist focusing on biomarker development and the clinical therapeutics of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS), the largest and most active consortium in the world dedicated to ALS. He continues to direct the NEALS outcomes and clinical monitoring cores and is currently the principal investigator for two multicenter clinical trials, as well as for a biomarker study evaluating the effectiveness of electrical impedance myography in measuring ALS disease progression.

In 2014, Dr. Shefner received the Sheila Essey Award for ALS Research, presented annually by the American Academy of Neurology and the ALS Association. He has published approximately 200 papers in peer-reviewed journals and has served on multiple grant review panels.

“I am pleased to join the TikoMed Scientific Advisory Board, and look forward to assisting the company in reaching the next stage of clinical development. The company has an ambitious plan to design and implement a study with solid and reliable readouts to ensure accurate assessment of their experimental therapeutic agent,” says Professor Shefner.

The SAB will advise management as Phase 2 clinical development of ILB progresses. The Board will integrate highly experienced clinicians as well as seasoned industrial scientific leaders in the field, they state.

Photo of Jeremy Shefner: Barrow Neurological Institute

Advertisement